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Abstract
Background

Accuracy in translating the International Prostate Symptom Score (IPSS) into different languages is essential to ensure that it is
comparable to the original version and acceptable to the target population. We aimed to develop and validate a Swahili version
of the IPSS (sIPSS).

Methods

We conducted a cross-sectional study involving 53 patients presenting with lower urinary tract symptoms to the Aga Khan Hospital in Dar es Salaam, Tanzania, from April through December 2018. We enrolled 53 patients with confirmed benign prostatic
hypertrophy and 32 control patients with suspected or confirmed urolithiasis. We assessed the face validity and discriminative
validity of the sIPSS using standard statistical constructs, including Cronbach’s alpha, intraclass correlation coefficients (ICC), the receiver operating characteristic curve, and Spearman’s rank correlation coefficient. Test–retest reliability was assessed by comparing
baseline sIPSS scores with those obtained after 1 week for all participants, and sensitivity to change was assessed by comparing
baseline scores to those at 4 to 6 weeks after treatment in the BPH group.

Results

The sIPSS had excellent internal validity (Cronbach’s alpha, 0.86), comparable to that of the original IPSS. The test–retest reliability
of the sIPSS was high (ICC, 0.84), and the mean improvement in sIPSS score 4 to 6 weeks after treatment was 9.7±6.4.

Conclusions

For use in the Tanzanian population, the sIPSS is reliable, valid, and sensitive to change.

Keywords: Cronbach’s alpha, internal consistency, Swahili, International Prostate Symptom Score, test–retest reliability,
validity, Tanzania

Introduction

B

enign prostatic hypertrophy (BPH) is a common condition, and its prevalence has increased up to 50% in
the past 20 years among men older than 50 years.[1] BPH
is clinically important when it is associated with symptoms,
such as lower urinary tract symptoms (LUTS).
Given the clinical relevance of BPH symptoms, efforts
have been made to standardize the evaluation of BPH symptoms and assess their impact on patient well-being. The
measurement committee of the American Urological As-
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sociation (AUA) designed and validated a symptom index
(AUA-7) for BPH,[2],[3] and the International Consultation
on Benign Prostatic Hyperplasia (26-27 June 1991 in Paris,
France) recommended that research questionnaires include
patients’ perceptions regarding the impact of symptoms on
quality of life (QoL).[4] Subsequently, the International Scientific Committee, under the patronage of the World Health
Organization and the International Union Against Cancer,
endorsed the use of the AUA-7 with additional questions on
QoL.[4] This final tool is what is known as the International
Prostate Symptom Score (IPSS) questionnaire.[5],[6]
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The IPSS is widely used in research and clinical settings to assess the severity of LUTS, guide treatment, and
evaluate patients’ responses to treatment. The IPSS is selfadministered and requires only a few minutes to complete.
Self-administration may reduce the biases that could arise
if patient responses were influenced by physician or health
worker administration; thus, compared with other instruments, the IPSS may more accurately reflect patients’ perceptions of LUTS.[7] The English (US) version is the original IPSS questionnaire, and several translations are now in
widely used in clinical practice and research.[2],[3],[8]-[11]
Accuracy is essential when translating the IPSS into different
languages to ensure that the translated version is both comparable to the original version and acceptable to the target
population. It is particularly important that the IPSS correctly categorizes patient symptoms because this information is
used to guide treatment.
In a recent study conducted in India, Jindal et al.[12]
showed that patients who did not use English as their first
language misinterpreted the IPSS and that this significantly
affected patient outcomes. Johnson et al.[13] showed that
patients who had low education levels often misinterpreted
questions on the AUA-7 and, therefore, received inappropriate treatment. Swahili is the official language of Tanzania
and is the language of instruction in primary and secondary
schools and often at postsecondary institutions. The majority
of Tanzanians use Swahili in their day-to-day communication. However, to the best of our knowledge, before the study
reported herein, there was no validated Swahili version of
the IPSS questionnaire. This study aimed to develop a Swahili version of the IPSS (sIPSS) and assess the validity and
reliability of this new translated version.

Methods
We conducted a cross-sectional study of patients who presented to the Aga Khan Hospital in Dar es Salaam, Tanzania, with lower urinary tract symptoms. The questionnaire
underwent translation into Swahili followed by a pilot study.
The internal consistency (Cronbach’s alpha), validity (Spearman’s rank correlation), test–retest reliability (intraclass correlation [ICC]), and sensitivity to change (effect size index,
[ESI]) of the final questionnaire were assessed.

Translation of the International Prostate
Symptoms Score into Swahili
The IPSS asks patients 7 questions about their experiences,
in the past month, respectively, with 7 potential LUTS: frequency of urination, incomplete bladder emptying, straining, intermittency, urgency, nocturia, and weak urine
stream. For each question, the patient can choose 1 of 6 responses on a scale from 0 to 5 (0 = did not experience this
symptom in the past month; 1 = at least once; 2 = less than
half of the time; 3 = half of the time; 4 = more than half the
time; 5 = always). The total symptom score is the sum of the
responses to the 7 questions. The severity of LUTS, based on
the total score, can be graded as mild (0-7), moderate (8-19),
or severe (20-35).[2]

journal.cosecsa.org

Original Research

The translation of the English version of the IPSS into
Swahili was guided by a standardized process provided by
Mapi Research Trust. The English IPSS was translated into
Swahili by a professional translator, followed by 2 independent back-translations by healthcare professionals. The original and back-translated questionnaires were compared by
the study’s principal investigator, and modifications were
made based on suggestions from the individuals involved in
this process. The final sIPSS was piloted with 10 BPH patients who were interviewed to evaluate their comprehension
of the questions and to identify unclear words or phrases. All
10 participants understood the questionnaire well and found
the words and phrasing to be clear.[8]

Study sample
We validated the sIPSS using questionnaire responses from
85 patients recruited from the Aga Khan University Hospital, Tanzania, from April through December 2018. The study
included 53 patients aged 50 years and older with LUTS and
urologist-confirmed BPH. Also included were 32 control
patients, aged 18 to 49 years, with suspected or confirmed
urolithiasis. BPH diagnoses were based on laboratory investigations or clinical criteria garnered from medical historytaking and physical examination (including digital rectal
examination). Exclusion criteria were as follows: comorbid
conditions, such as uncontrolled diabetes mellitus, use of
diuretics, history of previous pelvic trauma, previous surgical procedures for BPH or prostate cancer, and inability to
understand questions on the sIPSS. Patients with prostatitis
or BPH were not recruited as controls.
Table 1. Sociodemographic variables and sIPSS scores of
patients with benign prostatic hyperplasia and control
patients with confirmed or suspected urolithiasis at a
private general hospital in Dar es Salaam, Tanzania, April
through December 2018
Cases
(n=53)

Controls
(n=32)

P value

59.6±8.0

33.2±6.9

<0.001

None

2 (3.8)

1 (3.1)

Primary

4 (7.5)

3 (9.4)

Secondary

13 (24.5)

6 (18.8)

Tertiary

34 (64.2)

22 (68.8)

0-7

14 (26.4)

28 (87.5)

8-21

29 (54.7)

3 (9.4)

22-35

10 (18.9)

1 (3.1)

Variable
Age, years,
mean ± SD
Education level

0.93

sIPSS score

<0.001

Values are n (%) unless otherwise indicated.
sIPSS, Swahili version of the International Prostate Symptom Score
questionnaire; SD, standard deviation
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24

3 (9.4)

1 (3.1)

1 (3.1)

1 (3.1)

0 (0)

0 (0)

1 (3.1)

Study procedures
The sIPSS was administered at baseline and at 2 followup time points, namely, 1 week after baseline (to evaluate
test–retest reliability) and 4 to 6 weeks after baseline (to
evaluate sensitivity to change). The data from the questionnaires were entered into Excel (Microsoft Corp.,
Redmond, WA, USA) spreadsheets, cleaned, and finally
transferred to SPSS Statistics for Windows, version 25.0
(IBM Corp., Armonk, NY, USA) for analysis.

Cases

5 (9.4)

3 (5.7)

8 (15.1)

5 (9.4)

6 (11.3)

5 (9.6)

4 (7.5)

Controls

0 (0)

1 (3.1)

0 (0)

0 (0)

0 (0)

0 (0)

1 (3.1)

5 (9.4)

6 (11.3)

6 (11.3)

2 (3.8)

7 (13.2)

3 (5.8)

7 (13.2)

The study protocol was approved by the Ethics and
Research Committee of the Aga Khan University; permission was obtained from Mapi Research Trust to
translate the IPSS into Swahili. All study participants
provided written consent before starting any study activity.

9 (28.1)

26 (81.2)

24 (75)

29 (90.6)

27 (84.4)

20 (62.5)

All values are n (% of group size).

2 (3.8)
(7) Nocturia

20 (38.5)
(6) Hesitancy

12 (22.6)
(5) Weak stream

21 (39.6)
(4) Urgency

17 (32.1)
(3) Intermittency

10 (18.9)
(2) Frequency

13 (24.5)
(1) Emptying

sIPSS, Swahili version of the International Prostate Symptom Score questionnaire

14 (20.8)
13 (40.6)
14 (26.4)

10 (19.2)
2 (6.2)
7 (13.5)

14 (26.4)
3 (9.4)
4 (7.5)

9 (17.0)
2 (6.2)
6 (11.3)

4 (7.5)
4 (12.5)
11 (20.8)

10 (18.9)
8 (25)
13 (24.5)

7 (13.2)
6 (18.8)
12 (22.6)
23 (71.9)

Controls
Cases

Data analysis

Responses for question 7: 0, None; 1, 1 time; 2, 2 times; 3, 3 times; 4, 4 times, 5, At least 5 times

15 (28.3)
13 (15.6)

7 (13.5)
2 (6.2)

10 (18.9)
4 (12.5)

10 (18.9)
0 (0)

7 (13.2)
1 (3.1)

11 (20.8)
2 (6.2)

11 (20.8)
2 (6.2)

Cases
Controls
Controls
Cases

Cases

2
1
0

Responses for questions 1-6: 0, Not at all; 1, Less than 1 in 5 times; 2, Less than half of the time; 3, Half of the time; 4, More than half of the time; 5, Almost always

1 (3.1)

1 (3.1)

0 (0)

0 (0)

0 (0)

1 (3.1)

0 (0)

Controls

4
Cases

5

Controls

Dar es Salaam, Tanzania: Swahili International Prostate Symptom Score

3
sIPSS score
Questionnaire
item

Table 2. The distribution of responses to individual sIPSS items among patients with benign prostatic hyperplasia (n=53) and control patients with confirmed or suspected
urolithiasis (n=32) at a private general hospital in Dar es Salaam, Tanzania, April through December 2018

Original Research

To characterize study participants, descriptive statistics
were generated using frequencies and percentages for
categorical variables and means and standard deviations
(SDs) for continuous variables. The internal consistency
of the sIPSS was evaluated using Cronbach’s alpha coefficient; test–retest reliability was evaluated using the ICCs
of paired data of participant responses at baseline and 1
week after baseline. The sensitivity to change of the sIPSS
was evaluated by comparing the mean scores of BPH patients before and after treatment (either surgical or medical) using paired-samples t tests. Sensitivity to change
was also assessed using Guyatt’s statistic, obtained by
dividing the mean differences between baseline and follow-up sIPSS scores by the mean SD of scores in the control group. Sensitivity to change (ESI) was calculated by
dividing the mean difference in scores before and after
treatment by the SD. The sensitivity and specificity of the
sIPSS were evaluated by calculating the area under the
receiver operating characteristic (AUROC) curve using
a cutoff value of 7.5.[10]
Sample size
The minimum sample size was calculated using the following formula:
n = 1 + 2(Zα + Zβ)2k
(lnC0)2(k − 1)
Where,
n = the expected sample size,
α = the probability of type I error;
β = the probability of type II error (1 − power of the test);
and k = the number of replicates.
Using a significance level of 0.05 and 80% power, a
specified correlation coefficient of 0.9, and an expected
correlation coefficient of 0.95, we calculated a minimum
sample size of 49 participants.

EAST and CENTRAL AFRICAN Journal of Surgery | VOLUME 26 | NUMBER 1 | JAN-MAR 2021

journal.cosecsa.org

Dar es Salaam, Tanzania: Swahili International Prostate Symptom Score

Original Research

journal.cosecsa.org

−0.04
0.4
Paired-samples t tests yielded no statistically significant differences

P<0.001 for all ICCs

b

ICC, intraclass correlation coefficient; QoL, quality of life; SD, standard deviation; sIPSS, Swahili version of the International Prostate Symptom Score questionnaire

3.7±1.8
2.1±2.6
3.7±1.8
2.4±2.8
1.00
0.92
0.94
0.85
0.92
(8) QoL

a

0.1
<0.001
2.4±1.3
1.4±1.5
2.5±1.3
1.4±1.5
0.92
0.86
0.92
(7) Nocturia

0.99

0.99

<0.001
<0.001
1.6±1.7
0.4±1.1
1.6±1.7
0.4±1.1
1.00
1.00
1.00
(6) Hesitancy

1.00

1.00

<0.001
<0.001
2.3±1.6
0.5±1.1
2.3±1.6
0.5±1.1
1.00
1.00
1.00
(5) Weak stream

1.00

1.00

<0.001
<0.001
1.6±1.7
0.2±0.9
1.6±1.7
0.2±0.9
1.00
1.00
1.00
(4) Urgency

1.00

1.00

<0.001
<0.001
2.0±1.9
0.2±0.5
2.0±1.9
0.2±0.5
1.00
1.00
1.00
(3) Intermittency

1.00

1.00

<0.001
<0.001
2.0±1.5
0.6±1.0
2.0±1.5
0.6±1.0
1.00
1.00
1.00
(2) Frequency

1.00

1.00

0.1
<0.001
2.0±1.6
0.5±1.0
2.1±1.7
0.5±1.0
0.95
0.91
0.94

1.00

1.00

Cases
Controls
Cases
Controls
Cases
Controls
Cases
Controls
Cases

(1) Emptying

Questionnaire item

Overall

Controls

Mean differenceb
Mean ± SD
retest score
Mean ± SD
test score
Internal consistency
ICCa

Table 3. Validity and reliability of the sIPSS when evaluated with patients with benign prostatic hyperplasia (n=53) and control patients with confirmed or suspected urolithiasis
(n=32) at a private general hospital in Dar es Salaam, Tanzania, April through December 2018

Results
In total, 85 patients (53 BPH patients and 32 control patients) participated in the study. Compared with the control group, the BPH group was significantly older (mean
difference, 26.4 years; P<0.001) and had a significantly
higher mean baseline sIPSS (P<0.001) (Table 1). At baseline, the sIPSS scores ranged from 1 to 33 in the BPH
group and 0 to 31 in the control group; thus, neither cases
nor controls scored the maximum possible IPSS score of
35 (Table 2).
Values of the receiver operating characteristic curve
for individual items on the sIPSS ranged from 0.64 to
0.84, indicating that these items achieved a high level of
discrimination between BPH patients and control patients. The AUROC for the sIPSS was 0.78 (standard error of the mean, 0.04; 95% confidence interval, 0.70-0.87)
(Figure 1). The sIPSS correlated highly with the Swahili
QoL question (Spearman rank correlation coefficient,
0.72; P<0.001).
The reliability of the sIPSS was high, with ICC values
ranging from 0.85 to 1.00 in both the BPH and control
groups (Table 3). In the control group, the question regarding QoL yielded the lowest ICC value (0.85), whereas in the BPH group, the question regarding nocturia
yielded the lowest ICC value (0.86).
The sIPSS was sensitive to change in our patient population. The mean sIPSS score at baseline (i.e., before
treatment; mean [±SD], 14.0±8.4) was significantly higher than the mean score at follow-up (i.e., after treatment;
mean, 6.0±4.9; P<0.001) (Table 4). Our analysis of the
sIPSS’s sensitivity to change at 1 month after treatment
in the BPH group determined a mean improvement of
7.9±5.8, corresponding to an ESI of 0.94.
Significant differences were observed between the
BPH and control groups for individual items on the
sIPSS, indicating that the sIPSS had a high discriminative validity for distinguishing between patient groups
(Table 5). The mean difference between the scores of
the BPH and control groups was largest for the total
sIPSS score (P<0.001). The change in score from baseline to follow-up was also largest for the total sIPSS
score (P<0.001). Overall, the sensitivity and reliability
of the sIPSS are similar to those of the IPSS validated in
the United States (Table 6).

Discussion
The IPSS has been used in both clinical and research settings in Africa; however, its use has been limited owing
to low levels of literacy, particularly English language
literacy, in African populations.[14] To our knowledge, ours was the first study to validate an IPSS version
translated into an African language. The original IPSS
has been translated into several languages from regions
outside of Africa,[9],[11],[15]-[20] and studies of these
translated versions have demonstrated their validity and
reliability to be similar to those of the original IPSS. In
the present study, the mean age of BPH patients was
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59.6± 8.0 years and that of control patients was 33.2±6.8
years; these ages were similar to those reported in studies of the IPSS translated into Arabic,[10] Farsi,[17],[18],
Mandarin,[9] and Cantonese.[21]
In the present study, BPH and control patients had similar levels of education. Most of the patients in the present
study had at least a secondary level of education, and no
patients requested assistance to complete the questionnaire.
Studies have used a variety of methods to evaluate the validity of translated versions of the IPSS, most concluding that

the translated versions have good validity[22]; this accords
with our finding that the sIPSS had good discriminative validity to distinguish between BPH patients and control patients. Other studies have also found that translated versions
of the IPSS discriminate well between cases and controls. In
a comparison of BPH patients and healthy controls recruited
from Malaysia, Quek et al.[9] reported a significant difference in the mean total scores yielded by a Mandarin version
of the IPSS.[9] In Nigeria, authors showed that patients with
at least a secondary level of education were able to under-

Table 4. Mean scores before and after treatment, mean differences between the scores, effect size indices, and Guyatt statistics
of the sISPS components when evaluated with patients with benign prostatic hyperplasia (n=53) and control patients with
confirmed or suspected urolithiasis (n=32) at a private general hospital in Dar es Salaam, Tanzania, April through December
2018
Questionnaire
item

Mean ± SD score
before treatment

Mean ± SD score
after Treatment

Mean differencea

ESIb

Guyatt’s statisticc

(1) Emptying

2.0±1.7

1.1±1.1

0.9

0.57

0.93

(2) Frequency

2.0±1.5

0.8±0. 9

1.2

0.77

1.17

(3) Intermittency

1.9±1.9

0.9±1.2

1.0

0.54

2.17

(4) Urgency

1.6±1.6

0.6±0.8

0.9

0.58

1.04

(5) Weak stream

2.3±1.7

0.9±1.0

1.4

0.81

1.25

(6) Hesitancy

1.6±1.7

0.7±0.9

1.0

0.58

0.89

(7) Nocturia

2.5±1.3

1.2±1.0

1.3

0.99

0.90

sIPSS

14.1±8.3

6.2±4. 9

7.9

0.94

1.35

(8) QoL

3.7±1.8

1.5±1.1

2.21

1.22

0.80

P<0.001

a

n=52 for cases in the sensitivity to change/ESI analysis; ESI = mean difference/SD before treatment

b

Guyatt’s statistic = mean difference/SD of control group

c

ESI; effect size index; QoL, quality of life; SD, standard deviation; sIPSS, Swahili version of the International Prostate Symptom Score questionnaire

Table 5. Discriminative validity of the sIPSS components when evaluated with patients with benign prostatic hyperplasia
(n=53) and control patients with confirmed or suspected urolithiasis (n=32) at a private general hospital in Dar es Salaam,
Tanzania, April through December 2018
Questionnaire item

Test score, mean ± SD

Mean difference

P value

2.1±1.7

1.6

<0.001

0.6±1.0

2.0±1.5

1.4

<0.001

(3) Intermittency

0.2±0.5

2.0±1.9

1.8

<0.001

(4) Urgency

0.2±0.91

1.6±1.7

1.4

<0.001

(5) Weak stream

0.5±1.1

2.3±1.6

1.8

<0.001

(6) Hesitancy

0.4±1.1

1.6±1.7

1.2

<0.001

(7) Nocturia

1.4±1.5

2.5±1.3

1.1

<0.001

sIPSS

3.8±5.8

14.1±8.4

10.3

<0.001

(8) QoL

2.4±2.7

3.7±1.8

1.3

<0.001

Controls

Cases

(1) Emptying

0.5±1.0

(2) Frequency

QoL, quality of life; SD, standard deviation; sIPSS, Swahili version of the International Prostate Symptom Score questionnaire
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Table 6. Comparison between the original English IPSS and
the Swahili version evaluated with patients with benign
prostatic hyperplasia (n=53) and control patients with
confirmed or suspected urolithiasis (n=32) at a private
general hospital in Dar es Salaam, Tanzania, April through
December 2018
Statistical construct

IPSS version
English

Swahili

Correlation with item 8

0.77

0.72

Discriminatory power
(AUROC ± SE)

0.85±0.03

0.78±0.04

Test–retest reliability

0.92

0.84

Internal consistency
(Cronbach’s alpha)

0.86

0.92

Sensitivity to change
(effect size index)

1.44

0.94

P<0.001

P<0.001

Discriminative validity

AUROC, area under the receiver operating characteristic curve; IPSS,
International Prostate Symptom Score questionnaire; SE, standard error

stand and complete the IPSS without assistance.[23] Hammad et al.[10] reported that BPH patients had significantly
higher total scores than controls after completing an Arabic
language version of the IPSS.
We found that individual sIPSS items correlated strongly
with the QoL question on the sIPSS. This finding was similar
to that reported for the original IPSS[2] and the Arabic version of the IPSS,[10] and it confirms that the sIPSS is a valid
tool for assessing the impact of LUTS on the QoL of BPH
patients in our context.
Our assessments of the test–retest reliability and internal consistency of the sIPSS revealed high ICCs ranging
from 0.85 to 1.00, though none were statistically significant.
Higher ICCs correspond with higher levels of reliability. We
did not expect patient symptoms to change before retesting
1 week after baseline. Treatment was initiated for all BPH
patients around the time of retesting; treatment responses
to BPH-associated LUTS are generally gradual and reach
their peak about 1 month after treatment initiation.[1],[3]
Our findings regarding the test–retest reliability of the sIPSS
were similar to those calculated in studies of the IPSS versions translated into Mandarin (ICC, 0.98),[7] Spanish (ICC,
0.87),[18] Arabic (ICC, 88),[9] and Farsi (ICC, 0.78)[17] and
indicate that the sIPSS has excellent test–retest reliability.
We found that the Cronbach’s alpha values for individual
questions on the sIPSS ranged from 0.92 to 1.00. These values for internal consistency were somewhat better than those
reported for the original IPSS (ICC, 0.86) and are above the
threshold of 0.9 that is considered excellent for QoL assessment tools used in clinical settings.[24] Our findings regarding the internal consistency of individual items were similar
to those obtained by studies of the Mandarin (Cronbach’s
alpha, range, 0.90-0.98),[9] and Arabic (Cronbach’s alpha,
range, 0.78-0.85),[10] versions of the IPSS, and our values
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were higher than those reported from studies of the Farsi
(Cronbach’s alpha, 0.7),[17] and Urdu (Cronbach’s alpha,
0.72)[20] versions of the IPSS.
The ESI value (0.94) determined by our analysis indicates
that the sIPSS has a high sensitivity to change, although the
ESI of the sIPSS is lower than that reported for the original
IPSS (1.44).[9] A study of the Mandarin version of the IPSS
reported an ESI of 1.66,[9] while a study of the Spanish version of the IPSS reported an ESI of 2.52.[6] The high values
of the ESI reported for the Spanish version of the IPSS may
have been due to higher pretreatment IPSS scores in their
study sample compared with those observed in the present
study.
Our receiver operating characteristic curve analysis revealed that the individual sIPSS items had high discriminative validity for distinguishing between BPH patients and
control patients. We found AUROC values ranging from 0.64
to 0.84, which are comparable to the reported AUROC values (0.850±0.030) for the original IPSS,[2] higher than that
reported for the Spanish language IPSS (0.50±0.020),[6] but
lower than that reported for the Arabic IPSS (0.93±0.09).[10]
Thus, overall, our findings suggest that the sIPSS has high discriminative validity, comparable to other versions of the tool.

Limitations
Our study had limitations that may affect the interpretation of its findings. We recruited individuals who
were under the age of 50 as controls in view of excluding those with LUTS or BPH, conditions more commonly
afflicting older men.[2],[8] Thus, BPH and control patients
were not age matched. Nevertheless, this limitation does not
affect our finding that the sIPSS had validity and reliability
levels similar to those of the original IPSS because validation
of the original IPSS was also conducted among patients and
controls with dissimilar ages.[8]

Conclusions
Our study showed that the psychometric properties of the
sIPSS are similar to those of the original IPSS, as well as to
those of other translated versions of the IPSS. We found that
the sIPSS had excellent internal consistency, test–retest reliability, and sensitivity to change. We, therefore, conclude
that the sIPSS is a reliable and valid tool for assessing LUTS
in men diagnosed with BPH, and we recommend its use in
both clinical and research settings in Tanzanian and other
Swahili-speaking populations.
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